Regeneron Genetics Center
New ultra high-throughput DNA sequencing technology is making it economically feasible to sequence the DNA of tens of thousands of individuals, while health systems and investigators around the world have developed impressive resources for genetics discovery research including large-scale biobanks and sophisticated methods of analyzing health-related data. We believe the time is right to apply energy and novel methods to mine patient-consented sets of molecular and clinical information for medically-relevant associations.
The Regeneron Genetics Center, announced in January 2014, builds upon Regeneron's strengths in mouse genetics (VelociGene®; VelocImmune® and related technologies) and genetics-driven drug discovery and development (e.g. ARCALYST® (rilonacept) Injection, our Interleukin-1 blocker; alirocumab, our fully human antibody to the LDL cholesterol-regulating target PCSK9; and several other important pipeline medicines).
Our objective is to elucidate, on a large scale, genetic factors that cause or influence a range of human diseases. We believe that the knowledge we and our collaborators create can advance basic science around the world, provide clinically-valuable insights to physicians and patients, and identify novel targets for drug development.
Specific activities being scaled up will include gene sequencing projects, functional biology and mouse genetics for disease modeling, and translational research integrating genetics discovery research with the growing Regeneron pipeline. Program goals include target discovery, indication discovery, and patient-disease stratification through the use of human genetics and related genomic sciences. Our interests encompass a breadth of different areas such as Mendelian and family frameworks, large scale population genetics (both common and rare variants), and gene-gene interactions.
We seek to collaborate with leading health systems and academic and government research groups in this exciting initiative. The first, foundational collaboration, with the Geisinger Health System, was announced in January 2014. Read the press release.
Regeneron seeks collaborations with health-care providers and academic and government researchers who can contribute patient-consented samples, from volunteers, with well-annotated clinical data. For more information, contact email@example.com.
Regeneron is looking for talented and motivated individuals to join the company, complement internal teams and resources, and help lead these exciting programs and expanded efforts.
For more information and a list of our openings, visit our Careers website.
Aris Baras, M.D.
Director, R&D Initiatives
Deputy Head, Regeneron Genetics Center
John Overton, Ph.D.
Associate Director, Sequencing and Lab Operations
Jeffrey Reid, Ph.D.
Director, Genome Informatics
Regeneron Genetics Center Founders and Regeneron Genetics Steering Committee
George Yancopoulos, M.D., Ph.D.
Aris Baras, M.D.
Aris Economides, Ph.D.
Scott Mellis, M.D., Ph.D.
Andrew Murphy, Ph.D.
Robert Phillips, Ph.D.
Neil Stahl, Ph.D.